Lista de obras -

A Novel Use of Dignity Therapy ⬇️

artículo científico publicado el 1 de diciembre de 2011

A comparative study of the MATRICS and IntegNeuro cognitive assessment batteries.

artículo científico publicado en 2010

A contribution of novel CNVs to schizophrenia from a genome-wide study of 41,321 subjects

Altered threat and safety neural processing linked to persecutory delusions in schizophrenia: a two-task fMRI study

artículo científico publicado en 2015

An assessment of injection site reaction and injection site pain of 1-month and 3-month long-acting injectable formulations of paliperidone palmitate

artículo científico publicado en 2018

An examination of neurocognition and symptoms as predictors of post-hospital community tenure in treatment resistant schizophrenia

artículo científico publicado en 2016

Attention shaping: a reward-based learning method to enhance skills training outcomes in schizophrenia

artículo científico publicado en 2008

Bifactor Modeling of the Positive and Negative Syndrome Scale: Generalized Psychosis Spans Schizoaffective, Bipolar, and Schizophrenia Diagnoses.

artículo científico publicado en 2018

Caregiver burden in schizophrenia following paliperidone palmitate long acting injectables treatment: pooled analysis of two double-blind randomized phase three studies

artículo científico publicado en 2017

Comparison of Capillary and Venous Drug Concentrations After Administration of a Single Dose of Risperidone, Paliperidone, Quetiapine, Olanzapine, or Aripiprazole

scientific article published on July 2016

Comparison of Capillary and Venous Plasma Drug Concentrations After Repeated Administration of Risperidone, Paliperidone, Quetiapine, Olanzapine, or Aripiprazole

artículo científico publicado en 2016

Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects

artículo científico publicado en 2016

Effect of parental age on treatment response in adolescents with schizophrenia

artículo científico publicado en 2013

Effectiveness of a two-phase cognitive rehabilitation intervention for severely impaired schizophrenia patients

artículo científico publicado en 2005

Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study

artículo científico publicado en 2016

Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia: A Randomized Clinical Trial

artículo científico

Efficacy and safety of paliperidone extended release in adolescents with schizophrenia: a randomized, double-blind study

artículo científico publicado en 2014

Efficacy and safety of paliperidone palmitate 3-month formulation in Latin American patients with schizophrenia: A subgroup analysis of data from two large phase 3 randomized, double-blind studies

scientific article published on 01 November 2019

Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study

artículo científico publicado en 2017

Evaluation of Potentially Prolactin-Related Adverse Events and Sexual Maturation in Adolescents with Schizophrenia Treated with Paliperidone Extended-Release (ER) for 2 Years: A Post Hoc Analysis of an Open-Label Multicenter Study

artículo científico publicado en 2017

Genome-wide association study of paliperidone efficacy

artículo científico publicado en 2017

Group Cognitive Behavioral Therapy for Delusions: Helping Patients Improve Reality Testing

Incidence and time course of extrapyramidal symptoms with oral and long-acting injectable paliperidone: a posthoc pooled analysis of seven randomized controlled studies

artículo científico publicado en 2013

Large-scale candidate gene study to identify genetic risk factors predictive of paliperidone treatment response in patients with schizophrenia

artículo científico publicado en 2015

Long-Term Safety of Paliperidone Extended Release in Adolescents with Schizophrenia: An Open-Label, Flexible Dose Study

artículo científico publicado en 2015

Mapping genomic loci implicates genes and synaptic biology in schizophrenia

artículo científico publicado en 2022

Measuring pathology using the PANSS across diagnoses: Inconsistency of the positive symptom domain across schizophrenia, schizoaffective, and bipolar disorder

artículo científico publicado en 2017

PM386. An Assessment of Injection Site Reactions and Injection Site Pain of Once-Every One Month and Three-Month Long-Acting Injectable Formulations of Paliperidone Palmitate.

artículo científico publicado en 2016

PM409. Paliperidone Palmitate 3-Monthly vs. 1-Monthly Injectable in Schizophrenia Patients with or without Prior Exposure to Oral Risperidone or Paliperidone.

artículo científico publicado en 2016

PM410. Comparison of 3-Monthly versus 1-Monthly Paliperidone Palmitate for Time to Onset and Time to Resolution of Extrapyramidal Symptoms in Patients with Exacerbated Schizophrenia.

artículo científico publicado en 2016

PM531. Population Pharmacokinetic/Pharmacodynamic Modeling of Paliperidone Palmitate 3-Month Formulation in Asian Population.

artículo científico publicado en 2016

PM532. Symptomatic Remission and Functional Recovery after Paliperidone Palmitate 3-monthly or 1-monthly treatment in Asian Patients with Exacerbated Schizophrenia.

artículo científico publicado en 2016

Paliperidone palmitate 3-month treatment results in symptomatic remission in patients with schizophrenia: a randomized, multicenter, double-blind, and noninferiority study

artículo científico publicado en 2017

Paliperidone palmitate: Japanese postmarketing mortality results in patients with schizophrenia

artículo científico publicado en 2016

Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: A phase-1, single-dose, randomized, open-label study

artículo científico publicado en 2015

Practical guidance for dosing and switching from paliperidone palmitate 1 monthly to 3 monthly formulation in schizophrenia

artículo científico

Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation

article by Abigail I Nash et al published 2019 in Neuropsychiatric Disease and Treatment

Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia

artículo científico publicado en 2009

Prospective dose selection and acceleration of paliperidone palmitate 3-month formulation development using a pharmacometric bridging strategy

artículo científico publicado en 2016

Reduced top-down influences in contour detection in schizophrenia

artículo científico publicado en 2006

SULT4A1 haplotype: conflicting results on its role as a biomarker of antipsychotic response

artículo científico publicado en 2014

Sparse factors for the positive and negative syndrome scale: which symptoms and stage of illness?

artículo científico publicado en 2015

The Open Translational Science in Schizophrenia (OPTICS) project: an open-science project bringing together Janssen clinical trial and NIMH data

artículo científico publicado en 2018

Lista de obras de

A Novel Use of Dignity Therapy ⬇️

A comparative study of the MATRICS and IntegNeuro cognitive assessment batteries.

A contribution of novel CNVs to schizophrenia from a genome-wide study of 41,321 subjects

Altered threat and safety neural processing linked to persecutory delusions in schizophrenia: a two-task fMRI study

An assessment of injection site reaction and injection site pain of 1-month and 3-month long-acting injectable formulations of paliperidone palmitate

An examination of neurocognition and symptoms as predictors of post-hospital community tenure in treatment resistant schizophrenia

Attention shaping: a reward-based learning method to enhance skills training outcomes in schizophrenia

Bifactor Modeling of the Positive and Negative Syndrome Scale: Generalized Psychosis Spans Schizoaffective, Bipolar, and Schizophrenia Diagnoses.

Caregiver burden in schizophrenia following paliperidone palmitate long acting injectables treatment: pooled analysis of two double-blind randomized phase three studies

Comparison of Capillary and Venous Drug Concentrations After Administration of a Single Dose of Risperidone, Paliperidone, Quetiapine, Olanzapine, or Aripiprazole

Comparison of Capillary and Venous Plasma Drug Concentrations After Repeated Administration of Risperidone, Paliperidone, Quetiapine, Olanzapine, or Aripiprazole

Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects

Effect of parental age on treatment response in adolescents with schizophrenia

Effectiveness of a two-phase cognitive rehabilitation intervention for severely impaired schizophrenia patients

Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study

Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia: A Randomized Clinical Trial

Efficacy and safety of paliperidone extended release in adolescents with schizophrenia: a randomized, double-blind study

Efficacy and safety of paliperidone palmitate 3-month formulation in Latin American patients with schizophrenia: A subgroup analysis of data from two large phase 3 randomized, double-blind studies

Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study

Evaluation of Potentially Prolactin-Related Adverse Events and Sexual Maturation in Adolescents with Schizophrenia Treated with Paliperidone Extended-Release (ER) for 2 Years: A Post Hoc Analysis of an Open-Label Multicenter Study

Genome-wide association study of paliperidone efficacy

Group Cognitive Behavioral Therapy for Delusions: Helping Patients Improve Reality Testing

Incidence and time course of extrapyramidal symptoms with oral and long-acting injectable paliperidone: a posthoc pooled analysis of seven randomized controlled studies

Large-scale candidate gene study to identify genetic risk factors predictive of paliperidone treatment response in patients with schizophrenia

Long-Term Safety of Paliperidone Extended Release in Adolescents with Schizophrenia: An Open-Label, Flexible Dose Study

Mapping genomic loci implicates genes and synaptic biology in schizophrenia

Measuring pathology using the PANSS across diagnoses: Inconsistency of the positive symptom domain across schizophrenia, schizoaffective, and bipolar disorder

PM386. An Assessment of Injection Site Reactions and Injection Site Pain of Once-Every One Month and Three-Month Long-Acting Injectable Formulations of Paliperidone Palmitate.

PM409. Paliperidone Palmitate 3-Monthly vs. 1-Monthly Injectable in Schizophrenia Patients with or without Prior Exposure to Oral Risperidone or Paliperidone.

PM410. Comparison of 3-Monthly versus 1-Monthly Paliperidone Palmitate for Time to Onset and Time to Resolution of Extrapyramidal Symptoms in Patients with Exacerbated Schizophrenia.

PM531. Population Pharmacokinetic/Pharmacodynamic Modeling of Paliperidone Palmitate 3-Month Formulation in Asian Population.

PM532. Symptomatic Remission and Functional Recovery after Paliperidone Palmitate 3-monthly or 1-monthly treatment in Asian Patients with Exacerbated Schizophrenia.

Paliperidone palmitate 3-month treatment results in symptomatic remission in patients with schizophrenia: a randomized, multicenter, double-blind, and noninferiority study

Paliperidone palmitate: Japanese postmarketing mortality results in patients with schizophrenia

Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: A phase-1, single-dose, randomized, open-label study

Practical guidance for dosing and switching from paliperidone palmitate 1 monthly to 3 monthly formulation in schizophrenia

Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation

Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia

Prospective dose selection and acceleration of paliperidone palmitate 3-month formulation development using a pharmacometric bridging strategy

Reduced top-down influences in contour detection in schizophrenia

SULT4A1 haplotype: conflicting results on its role as a biomarker of antipsychotic response

Sparse factors for the positive and negative syndrome scale: which symptoms and stage of illness?

The Open Translational Science in Schizophrenia (OPTICS) project: an open-science project bringing together Janssen clinical trial and NIMH data